NO903925L - Fremgangsmaate for fremstilling av 3-(1-substituert-4-piperazinyl)-1h-indazoler samt anvendelse som legemidler. - Google Patents

Fremgangsmaate for fremstilling av 3-(1-substituert-4-piperazinyl)-1h-indazoler samt anvendelse som legemidler.

Info

Publication number
NO903925L
NO903925L NO90903925A NO903925A NO903925L NO 903925 L NO903925 L NO 903925L NO 90903925 A NO90903925 A NO 90903925A NO 903925 A NO903925 A NO 903925A NO 903925 L NO903925 L NO 903925L
Authority
NO
Norway
Prior art keywords
indazoles
piperazinyl
pharmaceuticals
substituted
procedure
Prior art date
Application number
NO90903925A
Other languages
English (en)
Other versions
NO903925D0 (no
Inventor
Joseph Thomas Strupczewski
Kenneth J Bordeau
Original Assignee
Hoechst Roussel Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Roussel Pharma filed Critical Hoechst Roussel Pharma
Publication of NO903925D0 publication Critical patent/NO903925D0/no
Publication of NO903925L publication Critical patent/NO903925L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO90903925A 1989-09-11 1990-09-10 Fremgangsmaate for fremstilling av 3-(1-substituert-4-piperazinyl)-1h-indazoler samt anvendelse som legemidler. NO903925L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/405,161 US4954503A (en) 1989-09-11 1989-09-11 3-(1-substituted-4-piperazinyl)-1H-indazoles

Publications (2)

Publication Number Publication Date
NO903925D0 NO903925D0 (no) 1990-09-10
NO903925L true NO903925L (no) 1991-03-12

Family

ID=23602539

Family Applications (1)

Application Number Title Priority Date Filing Date
NO90903925A NO903925L (no) 1989-09-11 1990-09-10 Fremgangsmaate for fremstilling av 3-(1-substituert-4-piperazinyl)-1h-indazoler samt anvendelse som legemidler.

Country Status (12)

Country Link
US (1) US4954503A (no)
EP (1) EP0417653A1 (no)
JP (1) JPH03167175A (no)
KR (1) KR910006279A (no)
AU (1) AU6229890A (no)
CA (1) CA2024996A1 (no)
FI (1) FI904419A0 (no)
IE (1) IE903286A1 (no)
IL (1) IL95633A0 (no)
NO (1) NO903925L (no)
PT (1) PT95260A (no)
ZA (1) ZA907174B (no)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5134236A (en) * 1987-08-07 1992-07-28 Hoechst-Roussel Pharmaceuticals Incorporated Phenylhydrazones as intermediates 1-phenyl-3-(1-piperazenyl)-1H-indazoles
NZ230068A (en) * 1988-07-29 1991-07-26 Dainippon Pharmaceutical Co Indazole-3-carboxylic acid esters and amides of diaza compounds having 6,7, or 8 ring members: preparatory processes and pharmaceutical compositions
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5561128A (en) * 1989-05-19 1996-10-01 Hoechst-Roussel Pharmaceuticals, Inc. N-[(4-(heteroaryl)-1-piperidinyl)alkyl]-10,11-dihydro-5H-dibenz[B,F]azepines and related compounds and their therapeutic utility
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5328920A (en) * 1991-04-17 1994-07-12 Hoechst-Roussel Pharmaceuticals Incorporated Substituted (pyridinylamino)-indoles
US5177088A (en) * 1991-04-17 1993-01-05 Hoechst-Roussel Pharmaceuticals Incorporated Substituted 3-(pyridinylamino)-indoles
US5225412A (en) * 1991-04-29 1993-07-06 Hoechst-Roussel Pharmaceuticals Incorporated Benzoisothiazole-and benzisoxazole-3-carboxamides
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
US5380944A (en) * 1992-03-04 1995-01-10 Kumiai Chemical Industry Co., Ltd. Benzhydrazone derivatives as an intermediate for the production of triazole derivatives
ES2187518T3 (es) * 1992-11-23 2003-06-16 Aventis Pharma Inc 3-(aminoalquilamino)-1-2-benzisoxazoles sustituidos y compuestos relacionados.
GB9305623D0 (en) * 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
US5681954A (en) * 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
GB9324244D0 (en) * 1993-11-25 1994-01-12 Merck Sharp & Dohme Therapeutic agents
US5889010A (en) * 1995-05-18 1999-03-30 Pfizer Inc. Benzimidazole derivatives having dopaminergic activity
DE69611783T2 (de) * 1995-06-06 2001-09-20 Aventis Pharma Inc Benzisoxazol- und indazol- derivate als antipsychotika
US6187774B1 (en) * 1996-03-04 2001-02-13 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and pharmaceutical applications thereof
US6982274B2 (en) 2001-04-16 2006-01-03 Eisai Co., Ltd. 1H-indazole compound
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
WO2004012738A1 (en) * 2002-08-05 2004-02-12 Sandoz Ag Novel salt and polymorphs of desloratadine hemifumarate
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
KR20070014184A (ko) * 2004-04-22 2007-01-31 베링거 인겔하임 인터내셔날 게엠베하 성기능 장애 치료용 신규 약제학적 조성물 ⅱ
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
JP2008511569A (ja) * 2004-09-03 2008-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 注意欠如活動過多障害の治療方法
EP1828182B1 (en) * 2004-11-29 2010-03-10 Warner-Lambert Company LLC Therapeutic pyrazolo[3,4-b]pyridines and indazoles
JP2008531714A (ja) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 不安障害の治療用及び/又は予防用の医薬組成物
US20060211685A1 (en) * 2005-03-04 2006-09-21 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
JP2008540356A (ja) * 2005-05-06 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬物乱用の治療方法
WO2006125042A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
EP1888070A1 (en) * 2005-05-19 2008-02-20 Boehringer Ingelheim International GmbH Method for the treatment of sexual dysfunctions due to medical conditions
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
US7923449B2 (en) * 2005-10-29 2011-04-12 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
CA2637531A1 (en) * 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
EA200802208A1 (ru) * 2006-05-09 2009-04-28 Бёрингер Ингельхайм Интернациональ Гмбх Применение флибансерина для лечения расстройств полового влечения в постклимактерический период
ES2336719T3 (es) 2006-06-30 2010-04-15 Boehringer Ingelheim International Gmbh Flibanserina para el tratamiento de la incontinencia urinaria y las enfermedades relacionadas.
CA2657043A1 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
CA2660476C (en) * 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
CA2661613C (en) * 2006-08-25 2016-01-26 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
US20090069337A1 (en) * 2007-08-15 2009-03-12 Memory Pharmaceuticals Corporation 3' substituted compounds having 5-ht6 receptor affinity
UY31335A1 (es) * 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100022581A1 (en) * 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
JP2014166961A (ja) * 2011-06-20 2014-09-11 Dainippon Sumitomo Pharma Co Ltd 新規インダゾール誘導体
CN104337812B (zh) 2013-07-29 2018-09-14 广东东阳光药业有限公司 取代的杂芳基化合物及其使用方法和用途
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
EP3609883B1 (en) * 2017-04-11 2022-06-29 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
US20240199555A1 (en) * 2021-03-19 2024-06-20 Centre National De La Recherche Scientifique Applications of biased ligands of the serotonin 5-ht7 receptor for the treatment of pain, multiple sclerosis and the control of thermoregulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA06083A (fr) * 1977-11-09 1981-06-30 Science Union & Cie Ste Franca Nouvelles pipérazines disubstituées, leurs procédés de préparation et les compositions pharmaceutiques les renfermant.
US4452799A (en) * 1981-12-23 1984-06-05 Mead Johnson & Company Benzisothiazole and benzisoxazole piperazine derivatives
US4536578A (en) * 1982-04-09 1985-08-20 Hoechst-Roussel Pharmaceuticals Inc. 1-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-(substituted)piperazines
US4524206A (en) * 1983-09-12 1985-06-18 Mead Johnson & Company 1-Heteroaryl-4-(2,5-pyrrolidinedion-1-yl)alkyl)piperazine derivatives
US4590196A (en) * 1984-08-23 1986-05-20 Bristol-Myers Company Analgesic 1,2-benzisothiazol-3-ylpiperazine derivatives
NL8601494A (nl) * 1985-06-22 1987-01-16 Sandoz Ag Thiazolen, hun bereiding en farmaceutische preparaten die ze bevatten.
EP0302423A3 (en) * 1987-08-07 1991-01-09 Hoechst-Roussel Pharmaceuticals Incorporated 1-phenyl-3-(1-piperazinyl)-1h-indazoles, a process and intermediates for their preparation, and the use thereof as medicaments
NZ230045A (en) * 1988-08-05 1990-11-27 Janssen Pharmaceutica Nv 3-piperazinylbenzazole derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
FI904419A0 (fi) 1990-09-07
PT95260A (pt) 1991-05-22
AU6229890A (en) 1991-03-14
JPH03167175A (ja) 1991-07-19
CA2024996A1 (en) 1991-03-12
NO903925D0 (no) 1990-09-10
IE903286A1 (en) 1991-04-10
US4954503A (en) 1990-09-04
ZA907174B (en) 1991-06-26
EP0417653A1 (en) 1991-03-20
IL95633A0 (en) 1991-06-30
KR910006279A (ko) 1991-04-29

Similar Documents

Publication Publication Date Title
NO903925L (no) Fremgangsmaate for fremstilling av 3-(1-substituert-4-piperazinyl)-1h-indazoler samt anvendelse som legemidler.
NO902933D0 (no) Fremgangsmaate for fremstilling av 2-(aminoaryl)indoler ogindoliner samt anvendelse som medikamenter.
NO902003L (no) Fremgangsmaate for fremstilling av n-heteroaryl-4-quinolinaminer.
NO885454L (no) Fremgangsmaate for fremstilling av triklormonosilan.
NO901554L (no) Fremgangsmaate for fremstilling av dinatrium-cefodizim.
NO894210L (no) Fremgangsmaate for fremstilling av kinolyloxazol-2-oner.
NO894649L (no) Fremgangsmaate for fremstilling av (s)-alfa-ethyl-2-oxo-1-pyrrolidinacetamid.
NO903474D0 (no) Fremgangsmaate for fremstilling av neoalkyltrioltriestere.
DK135988D0 (da) 2,5-dihydropyrroler, fremgangsmaader til deres fremstilling samt deres anvendelse som herbicider
NO895032D0 (no) Fremgangsmaate for fremstilling av 2-benzotiazoliner.
NO905444L (no) Fremgangsmaate til fremstilling av oksazolderivater.
NO901505D0 (no) Fremgangsmaate for fremstilling av titandioksyd.
NO903043D0 (no) Fremgangsmaate for fremstilling av kromanderivater.
NO890159D0 (no) Fremgangsmaate for fremstilling av 1-alkyl-5-nitroimidazoler.
NO903207D0 (no) Fremgangsmaate for fremstilling av halogenaminoaromatiske derivater.
NO903347D0 (no) Fremgangsmaate for fremstilling av 14,17alfa-ethano- og ethanooestratriener.
NO891574D0 (no) Fremgangsmaate for fremstilling av farmasoeytisk anvendbareforbindelser.
NO903591D0 (no) Fremgangsmaate for fremstilling av pyrido(3,4-b)(1,4)benzoksazepiner samt anvendelse som medikamenter.
NO901067D0 (no) Fremgangsmaate for fremstilling av tiofener.
NO902762D0 (no) Fremgangsmaate for fremstilling av 5-fenyl-2-furan derivater.
NO895040L (no) Fremgangsmaate for fremstilling av polyhydroxybenzyloxypropanolaminer.
NO900969L (no) Fremgangsmaate for fremstilling av n-allymetatrifluormetylanilin.
NO900219L (no) Dihydroksybenzofenon-oksim, samt fremgangsmaate for fremstilling av slike oksimer.
NO901892D0 (no) Fremgangsmaate for fremstilling av (2,1-c)(1,3)-benzodiazepiner og deres anvendelse som medikamenter.
NO904070D0 (no) Fremgangsmaate for fremstilling av alkanfenoner.